Shandong Boan Biotechnology Company., Limited. Class H (HK:6955) has released an update.
Shandong Boan Biotechnology Co., Ltd. has announced the approval to commence clinical trials in China for BA1302, a novel antibody-drug conjugate targeting CD228 in advanced solid tumors. This marks the first CD228-targeted ADC to enter clinical trials in China, with BA1302 showing promise in preclinical studies due to its potent anti-tumor activity, favorable pharmacokinetics, and good safety profile. BA1302 stands as the only such ADC at the clinical stage worldwide, potentially offering a new effective treatment for various solid tumors.
For further insights into HK:6955 stock, check out TipRanks’ Stock Analysis page.
